Previous 10 | Next 10 |
“We have been living and illusion that revenue and growth equals success. Even the press goes for it” -Bill Gurley 1) Invitae: The Amazon of Genetics? Invitae’s social mission is to provide affordable genetic testing for all. This has somehow earned the...
A handful of genetic testing stocks rolled off all-time highs last month. Shares of NeoGenomics (NASDAQ: NEO) led the peer group by shedding 23.5% in September, according to data from S&P Global Market Intelligence . That was closely followed by a tumble of 20.6% for shares of Inv...
SAN FRANCISCO , Sept. 9, 2019 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the availability of Detect Hereditary Pancreatic Cancer, a testing program that offers no-charge genetic testing and counseling to patients with pancreatic ca...
Invitae (NYSE: NVTA ) has priced its $300M (from $200M) aggregate principal amount of 2.00% convertible senior notes due 2024 in a private offering. More news on: Invitae Corporation, Healthcare stocks news, Read more ...
SAN FRANCISCO , Sept. 6, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) announced the pricing on September 5, 2019 of $300.0 million aggregate principal amount of 2.00% convertible senior notes due 2024 (the "notes") in a private offering to qualified institutional buyers pursu...
SAN FRANCISCO , Sept. 4, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced its intention to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of convertible senior notes due 2024 (the "notes") in a private offering ...
Biogen (NASDAQ: BIIB ) and Invitae (NYSE: NVTA ) announces that SMA STAT, a new, rapid-turnaround genetic test for spinal muscular atrophy (SMA), will be offered at no charge to individuals in the U.S. as part of the SMA Identified program. More news on: Biogen Inc., Invitae Co...
New SMA STAT genetic test reduces time to provide results from 21 to four days to aid in clinical care Early treatment of SMA has been shown to slow disease progression and improve or stabilize loss of motor function SMA Identified program offers genetic testing for SMA at no charge to i...
Rhythm Pharmaceuticals (NASDAQ: RYTM ) +29% on positive late-stage setmelanotide data . More news on: Rhythm Pharmaceuticals, Inc., Guardant Health, Inc., Weight Watchers International, Inc., Stocks on the move, Read more ...
Invitae (NYSE: NVTA ) is up 18% premarket on light volume after posting better-than-expected Q2 revenue after the close yesterday. Key points: More news on: Invitae Corporation, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...